financetom
Business
financetom
/
Business
/
Justice Dept officials' statements on Luigi Mangione broke court rules, judge says 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Justice Dept officials' statements on Luigi Mangione broke court rules, judge says 
Sep 24, 2025 9:52 AM

NEW YORK, Sept 24 (Reuters) - Public statements by

Justice Department officials about Luigi Mangione, the man

charged with killing an insurance executive last year, violated

a court rule meant to protect criminal defendants against

publicity that could prejudice a jury pool against them, the

judge overseeing the case said on Wednesday.

In a written order, Manhattan-based U.S. District Judge

Margaret Garnett instructed prosecutors to advise Deputy

Attorney General Todd Blanche to tell other Justice Department

officials that any further violations could result in

punishments including financial penalties or contempt of court.

Mangione, 27, has pleaded not guilty to charges of murdering

Brian Thompson, the former chief executive of UnitedHealth

Group's ( UNH ) insurance unit. Federal prosecutors are seeking

the death penalty in his case.

Garnett's order came after Mangione's defense lawyers in a

Tuesday night court filing said statements made by several Trump

administration officials had jeopardized his chances of getting

a fair trial.

They pointed to a Justice Department spokesperson's

September 19 X post referencing a comment President Donald Trump

made in a September 18 interview with Fox News asserting that

Mangione "shot someone in the back as clear as you're looking at

me."

"POTUS is absolutely right," the spokesperson, Chad

Gilmartin, said in the since-deleted post.

Mangione's lawyers also pointed to White House Press

Secretary Karoline Leavitt calling Mangione a "left-wing

assassin" in a September 22 news conference.

Neither the Justice Department nor the White House

immediately responded to requests for comment.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ares Management Fund Forms US Solar Energy Venture With Shell Subsidiary
Ares Management Fund Forms US Solar Energy Venture With Shell Subsidiary
Jul 28, 2025
05:56 PM EDT, 07/28/2025 (MT Newswires) -- Ares Management ( ARES ) said a fund managed by Ares Infrastructure Opportunities formed a joint venture with Shell's (SHEL) Savion Equity subsidiary to hold stakes in five US solar projects. The Tango Holdings venture will be 80% owned by the Ares Fund with the rest held by Savion. Tango will manage 496...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
VeriSign Shares Fall After Secondary Offering by Berkshire Hathaway Affiliates
VeriSign Shares Fall After Secondary Offering by Berkshire Hathaway Affiliates
Jul 28, 2025
05:58 PM EDT, 07/28/2025 (MT Newswires) -- VeriSign ( VRSN ) shares fall over 6% in afterhours trading session late Monday following a secondary offering of 4.3 million shares by affiliates of Berkshire Hathaway ( BRK/A ) (BRK.A, BRK.B). The company said the offering is taking place in order to keep Berkshire Hathaway's ( BRK/A ) stake in VeriSign (...
Bristol Myers, Bain Capital form new company to develop immunology drugs
Bristol Myers, Bain Capital form new company to develop immunology drugs
Jul 28, 2025
(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain's $300 million financing round, the companies said on Monday. The new company will work on five experimental drugs licensed from Bristol Myers, including a late-stage lupus treatment and a mid-stage psoriasis drug that has shown promise...
Copyright 2023-2026 - www.financetom.com All Rights Reserved